In our dataset, among patients with right-sided, RAS/BRAF wild-type disease treated chemotherapy plus anti-EGFR antibodies, the hazard ratios for early tumor shrinkage positivity and for depth of response in the highest quantile (≥Q3) were more favorable than those observed in patients treated with bevacizumab or chemotherapy alone (Table S5). Here, BRAF is linked to neoplasm.